Zacks Research Has Pessimistic Outlook of Neogen Q3 Earnings

Neogen Co. (NASDAQ:NEOG) – Analysts at Zacks Research cut their Q3 2026 EPS estimates for Neogen in a research report issued on Monday, May 12th. Zacks Research analyst R. Department now anticipates that the company will post earnings of $0.10 per share for the quarter, down from their prior estimate of $0.11. The consensus estimate for Neogen’s current full-year earnings is $0.38 per share. Zacks Research also issued estimates for Neogen’s FY2026 earnings at $0.39 EPS and FY2027 earnings at $0.44 EPS.

Neogen (NASDAQ:NEOG) last released its quarterly earnings results on Wednesday, April 9th. The company reported $0.10 earnings per share for the quarter, missing the consensus estimate of $0.12 by ($0.02). The company had revenue of $221.00 million during the quarter, compared to analyst estimates of $225.27 million. Neogen had a negative net margin of 52.12% and a positive return on equity of 2.89%. The firm’s quarterly revenue was down 3.4% compared to the same quarter last year. During the same quarter last year, the company earned $0.12 EPS.

Several other research analysts have also recently weighed in on the stock. Guggenheim reduced their price target on shares of Neogen from $15.00 to $13.00 and set a “buy” rating for the company in a report on Thursday, April 10th. Piper Sandler reduced their target price on shares of Neogen from $6.40 to $5.00 and set a “neutral” rating for the company in a report on Tuesday, April 22nd.

Neogen Stock Up 2.8%

Neogen stock opened at $6.56 on Thursday. The stock has a market capitalization of $1.42 billion, a PE ratio of -3.00 and a beta of 1.83. Neogen has a twelve month low of $3.87 and a twelve month high of $18.58. The company has a quick ratio of 2.46, a current ratio of 3.77 and a debt-to-equity ratio of 0.33. The company has a 50 day moving average of $6.82 and a 200-day moving average of $10.44.

Insider Buying and Selling

In other Neogen news, Director James P. Tobin bought 10,000 shares of Neogen stock in a transaction that occurred on Tuesday, April 22nd. The stock was acquired at an average price of $4.73 per share, for a total transaction of $47,300.00. Following the completion of the acquisition, the director now owns 37,474 shares of the company’s stock, valued at $177,252.02. This trade represents a 36.40% increase in their position. The purchase was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, Director James C. Borel bought 35,000 shares of Neogen stock in a transaction that occurred on Thursday, April 24th. The shares were acquired at an average price of $4.89 per share, with a total value of $171,150.00. Following the acquisition, the director now directly owns 60,474 shares of the company’s stock, valued at $295,717.86. The trade was a 137.39% increase in their position. The disclosure for this purchase can be found here. Over the last 90 days, insiders acquired 83,500 shares of company stock worth $431,525. 1.13% of the stock is owned by insiders.

Institutional Trading of Neogen

A number of large investors have recently added to or reduced their stakes in the company. Barclays PLC lifted its stake in Neogen by 129.8% in the 3rd quarter. Barclays PLC now owns 366,753 shares of the company’s stock valued at $6,165,000 after purchasing an additional 207,160 shares during the last quarter. Procyon Advisors LLC raised its stake in Neogen by 22.3% in the fourth quarter. Procyon Advisors LLC now owns 35,513 shares of the company’s stock valued at $431,000 after buying an additional 6,467 shares during the period. Avanza Fonder AB bought a new stake in Neogen in the fourth quarter valued at approximately $169,000. Inspire Investing LLC boosted its stake in shares of Neogen by 30.9% during the 4th quarter. Inspire Investing LLC now owns 36,383 shares of the company’s stock worth $442,000 after acquiring an additional 8,580 shares during the period. Finally, Blue Trust Inc. boosted its stake in shares of Neogen by 196.7% during the 4th quarter. Blue Trust Inc. now owns 3,368 shares of the company’s stock worth $41,000 after acquiring an additional 2,233 shares during the period. Institutional investors and hedge funds own 96.73% of the company’s stock.

About Neogen

Neogen Corporation, together with its subsidiaries, engages in the development, manufacture, and marketing of various products and services dedicated to food and animal safety worldwide. It operates through two segments, Food Safety and Animal Safety. The Food Safety segment offers diagnostic test kits and related products to detect dangerous and unintended substances in food and animal feed, including foodborne pathogens, spoilage organisms, natural toxins, food allergens, genetic modifications, ruminant by-products, meat speciation, drug residues, pesticide residues, and general sanitation concerns; and AccuPoint Advanced rapid sanitation test to detect the presence of adenosine triphosphate, a chemical found in living cells, as well as provides genomics-based diagnostic technology and software systems that help testers to objectively analyze and store their results and perform analysis on the results from multiple locations over extended periods.